List view / Grid view

Screening

 

article

Expert view: Managing the complexity of finding new targets and drugging the undruggable

5 September 2018 | By

Assessing targets that are unable – or rather, extremely difficult – to reach pharmacologically, has prevented researchers from achieving desired clinical successes, most notably in the realm of cancer research. However, many advances are being made to shedlight on these difficult yet desirable target areas.

whitepaper

Application Note: Evaluating the specificity and potency of PD-1 and PD-L1 blocking antibodies using AlphaLISA human and mouse PD-1/PD-L1 binding kits

5 September 2018 | By , , ,

Cancer immunotherapy utilises components of the immune system to treat cancer patients. These therapies are designed to work with a patient’s immune system to increase native anti-tumour responses. One type of immunotherapy relies on antibodies to bind to and inhibit the function of proteins expressed by the cancer cell...

article

Applications of high content screening in autophagy

4 September 2018 | By , ,

Autophagy is an important process to maintain cellular homeostasis and function.1 Basal levels of autophagy are essential for most cells to remove unwanted protein aggregates and damaged organelles in order to prevent diseases.2 However, sometimes cells are unable to maintain physiological stability as a consequence of altered autophagy, which leads…

article

Drug Target Review – Issue 3 2018

3 September 2018 | By

In this issue: pharmacological targeting of mitochondrial dysfunction in Parkinson’s disease, the evolving role of three dimensional in-vitro cell culture techniques in drug discovery, and NGS: hunting mysterious ‘Dark Matter Genome’ towards rewriting the rules of genetic diseases.